Boston Scientific Reports Higher Profit Margins In Q2, Lifts Guidance

Sep,16,,2019,Fremont, - ,Ca, - ,Usa,-,Boston

Stronger‑than‑expected sales and raised full‑year guidance underscore Boston Scientific Corporation‘s (NYSE:BSX) momentum—and hint at where its next product wins may come.

Boston Scientific on Wednesday reported second-quarter 2025 revenues of $5.06 billion, beating the consensus estimate of $4.89 billion.